[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pavmed Inc (PAVM)

Pavmed Inc (PAVM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,719
  • Shares Outstanding, K 996
  • Annual Sales, $ 70 K
  • Annual Income, $ 400 K
  • EBIT $ -24 M
  • EBITDA $ -24 M
  • 60-Month Beta 0.54
  • Price/Sales 69.28
  • Price/Cash Flow N/A
  • Price/Book 0.23

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.66
  • Number of Estimates 1
  • High Estimate $-0.66
  • Low Estimate $-0.66
  • Prior Year $-1.80
  • Growth Rate Est. (year over year) +63.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.39 +8.08%
on 07/22/26
6.65 -28.57%
on 07/16/26
-0.85 (-15.18%)
since 07/10/26
3-Month
3.85 +23.38%
on 06/18/26
7.31 -35.02%
on 05/11/26
-2.41 (-33.66%)
since 05/08/26
52-Week
3.85 +23.38%
on 06/18/26
28.44 -83.30%
on 01/21/26
-8.96 (-65.35%)
since 08/08/25

Most Recent Stories

More News
Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test

Concert's policy recognizes EsoGuard ® as the only esophageal precancer test meeting its coverage criteria

LUCD : 0.9611 (-0.62%)
PAVM : 4.75 (+0.21%)
Lucid Diagnostics to Participate in Upcoming Investor Conferences

NEW YORK , Aug. 4, 2026 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary...

LUCD : 0.9611 (-0.62%)
PAVM : 4.75 (+0.21%)
PAVmed to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 14, 2026

Conference Call and Webcast at 8:30 AM ET

LUCD : 0.9611 (-0.62%)
PAVM : 4.75 (+0.21%)
Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026

Conference Call and Webcast at 8:30 AM ET

LUCD : 0.9611 (-0.62%)
PAVM : 4.75 (+0.21%)
PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results

Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission

LUCD : 0.9611 (-0.62%)
PAVM : 4.75 (+0.21%)
Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results

Processed 3,177 EsoGuard ® tests and recognized 1Q26 revenue of $1.3 million, ending quarter with $45 million in proforma cash and a runway that extends into 2027 and past upcoming reimbursement...

LUCD : 0.9611 (-0.62%)
PAVM : 4.75 (+0.21%)
PAVmed to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 15, 2026

Conference Call and Webcast at 8:30 AM ET

LUCD : 0.9611 (-0.62%)
PAVM : 4.75 (+0.21%)
Lucid Diagnostics to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 14, 2026

Conference Call and Webcast at 8:30 AM ET

LUCD : 0.9611 (-0.62%)
PAVM : 4.75 (+0.21%)
Lucid Diagnostics Announces Closing of $18 Million Underwritten Offering of Common Stock

NEW YORK , April 24, 2026 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary...

LUCD : 0.9611 (-0.62%)
PAVM : 4.75 (+0.21%)
Lucid Diagnostics Announces $18 Million Underwritten Offering of Common Stock

NEW YORK , April 23, 2026 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary...

LUCD : 0.9611 (-0.62%)
PAVM : 4.75 (+0.21%)

Business Summary

PAVmed Inc. is a medical device company. Its diversified pipeline of products address unmet clinical needs, which consists of CarpX (TM) to treat carpal tunnel syndrome; NextFlo(TM) and NextCath(TM) a disposable infusion pump; PortIO(TM) and NextCath interventional radiology and Caldus (TM) tissue ablation...

See More

Key Turning Points

3rd Resistance Point 5.27
2nd Resistance Point 5.04
1st Resistance Point 4.90
Last Price 4.75
1st Support Level 4.53
2nd Support Level 4.30
3rd Support Level 4.16

See More

52-Week High 28.44
Fibonacci 61.8% 19.05
Fibonacci 50% 16.15
Fibonacci 38.2% 13.24
Last Price 4.75
52-Week Low 3.85

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.